AV Therapeutics, Inc. (AVTH) Commences Trading On The OTCQB
Small cap
Seeking Alpha Analyst Since 2010
Cancer therapeutics and vaccines developer AV Therapeutics announced that on Dec. 27, its common stock began trading on the OTC Market Group's OTCQB Marketplace under the symbol "AVTH."
The company has identified and patented Capridine, a chemo therapeutic drug that has demonstrated specific activity against prostate and colon cancer in preclinical models. Capridine is anticipated to be AV Therapeutics' frontline product - specifically in prostate cancer, for which limited chemotherapy treatments currently exist. Counting funding from the National Institutes of Health and the Department of Defense, more than $6 million has been invested in the development of the drug.
AV Therapeutics plans to enter Phase I trials for Capridine in the second quarter of 2014. These trials will be led by the Prostate Consortium, which is comprised of 16 leading academic medical centers in the United States.
AV Therapeutics is focused on the business of developing cancer therapeutics and immunotherapeutic vaccines that can be used alone or combined with prevalent treatment modalities like chemotherapy and radiation to treat active disease and prevent metastases and recurrence. The company's immune-therapeutics is based on the capability of certain proprietary reagents to re-educate or reprogram an immune system to target micro-metastases that were previously unidentified. AV Therapeutics plans to clinically develop both approaches for metastatic and early-stage prostate cancer.
For more information, visit the company's website at avtherapeutics.com
MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.